Expression and Clinical Significance of LRRC56, PANK2 and IGHD in Pancreatic Cancer
Study Details
Study Description
Brief Summary
Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer.
Objective： To explore the expression of IGHD、LRRC56 和 PANK2 in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer.
Methods： In this study, enzyme-linked immunosorbent assay (ELISA) was applied to detect the expression of IGHD、LRRC56 和 PANK2 in serum.Pancreatic cancer cells and pancreatic normal cell were compared. Using immunohistochemical staining to detect 30 pancreatic cancer tissues and 30 adjacent pancreatic cancer tissues, expression level and difference of IGHD、LRRC56 和 PANK2 protein between two groups was compared. Immunohistochemical staining results of pancreatic cancer tissues were combined with clinical and prognosis data of the pancreatic cancer patients. The chi-square test was used to analyze the influence factors of IGHD、LRRC56 and PANK2 expression level. Using Kaplan-Meier to analyze the patients' prognosis, Cox regression analysis was further used to analyze the influence factors and independent risk factors of patients' prognosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Methods：The expressions of IGHD, LRRC56 and PANK2 proteins in serum of about 30 patients with pancreatic cancer and more than 30 healthy controls were detected by ELISA kit, and the differences of IGHD, LRRC56 and PANK2 proteins were analyzed.Pancreatic cancer cells and pancreatic normal cell were compared. Using immunohistochemical staining to detect 30 pancreatic cancer tissues and 30 adjacent pancreatic cancer tissues, expression level and difference of IGHD、LRRC56 和 PANK2 protein between two groups was compared. Immunohistochemical staining results of pancreatic cancer tissues were combined with clinical and prognosis data of the pancreatic cancer patients. The chi-square test was used to analyze the influence factors of IGHD、LRRC56 and PANK2 expression level. Using Kaplan-Meier to analyze the patients' prognosis, Cox regression analysis was further used to analyze the influence factors and independent risk factors of patients' prognosis.
Pancreatic cancer is a disease of digestive system with a high degree of malignancy. The level of early diagnosis and therapeutic effect are limited by the research status of pancreatic adenocarcinoma. Conventional CT, MRI and other methods have a limited level of early diagnosis of pancreatic cancer, and EUS and endoscope-guided needle biopsy are in the stage of clinical trials. Studies on novel markers involve protein, miRNA, exosome, methylation, protein and genomics, but there is no mature and practical diagnostic method. Based on the current diagnosis, treatment and prognosis level of pancreatic cancer, I made a bold attempt to study the expression of IGHD, LRRC56 and PANK2 in pancreatic cancer and their relationship with clinical parameters and prognosis level, so as to screen molecular markers conducive to diagnosis, treatment and prognosis of pancreatic cancer and provide data support for improving the diagnosis and treatment level of pancreatic cancer.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| pancreatic cancer patients pathologically confirmed pancreatic cancer patients |
Procedure: immunohistochemical
Immunohistochemical staining results of pancreatic cancer tissues were combined with clinical and prognosis data of the pancreatic cancer patients.
|
| healthy people people without no neoplastic lesions and other organic diseases |
Outcome Measures
Primary Outcome Measures
- High expression of IGHD, LRRC56 and PANK2 are independent risk factors for poor prognosis in patients with pancreatic cancer. [2022.4-2023.10]
IGHD, LRRC56 and PANK2 were highly expressed in pancreatic cancer cells and tissues, but low in normal pancreatic cells and paracancer tissues. Patients with high expression of IGHD, LRRC56 and PANK2 proteins had lower prognosis. High expression of IGHD, LRRC56 and PANK2 proteins, T stage (T3T4), lymphatic metastasis and distant metastasis are independent risk factors for poor prognosis in patients with pancreatic cancer.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with pathologically confirmed pancreatic cancer
Exclusion Criteria:
-
noperable patients
-
other malignant tumors
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Affiliated Hospital of Nantong University | Nantong | Jiangsu | China |
Sponsors and Collaborators
- Affiliated Hospital of Nantong University
Investigators
- Study Director: Lu Y Yuhua, phd, The Affiliated Hospital of Nantong University
- Principal Investigator: Chen Q Qiyang, master, Nantong University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NTlyh76